Related Experiment Video

Updated: Jun 23, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Targeting guanine nucleotide exchange factors for novel cancer drug discovery

Sahar F Bannoura1, Husain Yar Khan1, Md Hafiz Uddin1

  • 1Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.

Expert Opinion on Drug Discovery
|June 17, 2024
PubMed
Abstract

Insights

Guanine nucleotide exchange factors (GEFs) are key regulators of Ras superfamily proteins, crucial in cellular functions and implicated in cancer. Targeting GEFs offers a promising strategy for novel cancer drug development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • Guanine nucleotide exchange factors (GEFs) control Ras superfamily proteins, acting as molecular switches vital for cellular functions.
  • These small GTPases (G proteins) are regulated by GEFs, which are implicated in various diseases, notably cancer.
  • The Ras superfamily includes Ras, Ran, Rho, Rab, and Arf GTPases, each with specific GEF regulators.

Purpose of the Study:

  • To review the roles and mechanisms of GEFs in cancer.
  • To present examples of GEFs significant in malignancy.
  • To discuss recent therapeutic targeting efforts for GEFs in cancer treatment.

Main Methods:

  • Literature review of GEF roles in cancer.
  • Illustration of GEF guanine exchange mechanism on small GTPases.
  • Discussion of therapeutic strategies targeting GEFs.

Main Results:

  • GEFs play significant roles in cancer development and progression.
  • Several GEFs are identified as critical players in various malignancies.
  • GEF-targeted drugs are predominantly in preclinical development.

Conclusions:

  • GEFs are emerging as promising therapeutic targets for novel cancer drug development.
  • Targeting GEF-mediated activation of small GTPases is a viable strategy.
  • Further biological understanding and advanced technologies are needed to accelerate GEF-targeted cancer drug discovery.
Keywords:
Drug discoveryRas proteinscancerguanine nucleotide exchange factorssmall GTPases

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
GTPases and their Regulation02:14

GTPases and their Regulation

Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
8.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K